U.S. Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6800+0.1800 (+5.14%)
At close: 4:00PM EDT
Sign in to post a message.
  • J
    John D
    From Investor Village for the longs

    TargetedOnc Interview of Lucy Gilbert on Mirv. + Bev.
    A more extended interview with Dr. Lucy Gilbert, lead investigator of the platinum agnostic cohort of Mirv. + Bev in FORWARD II:
    https://www.targetedonc.com/view/mirvetuximab-plus-bevacizumab-combo-appears-durable-in-platinum-agnostic-ovarian-cancer

    Gilbert: What is exciting is in the high FRα -expressing patients, responses were seen as early as 6 weeks. This is quite unusual in the recurrent setting. The reduction in tumor burden, as I said, started as early as 6 weeks, and the depth and duration of response was much higher in the FRα -high expressors. What is exciting is with a median duration of follow-up of 5.5 months, half the patients are still on trial. This is very encouraging. As an investigator with almost 30 years of experience, this is very unusual and exciting.
    In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
    In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
    www.targetedonc.com
    Bullish
  • A
    AnthonyH
    Dr. Berkenblit's presentation at the H.C. Wainwright Virtual Global Investment Conference was very good. Any number of pearls fell out of her answers to questions posed by the moderator. Unfortunately, only pathologists, medical oncologists and others deeply entrenched in this field of research are likely to fully appreciate the information she shared. Mirvetuximab soravtansine (IMGN853) is progressing as expected (and expectations are very high). IMGN632 is also further along than I realized. Excellent tolerance (a feature of most IMGN drug candidates as opposed to the more toxic alternatives presently on the market), activity as a monotherapy and in combination with established drugs and the good response in AML (a much larger market than BPDCN) are all very encouraging. She actually said they had a few "complete responses" (AML). IMGC936 has huge potential, continuing to show activity across a range of solid tumors. Their ability to "very specifically engineer" IMGN151 to address unmet need in a broader FRa population than their flagship drug is impressive. IMGN151 may prove to be the "sleeper" in their portfolio. I am happy with this investment.
  • W
    Wayne
    Sold this 5 years ago @ $15 and changes, now it's time to get back in. Three known companies with ADC technology, SGEN, IMMU (taken out recently) & IMGN, with recent study announcement, I'm willing to take another shot at this, go long!
    Bullish
  • A
    AnthonyH
    Not really banking on this but it did cross my radar ...

    On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment. Those companies have assets that are “largely de-risked and target high value indications", Piper Sandler said.

    On the list: Allogene Therapeutics (NASDAQ:ALLO), ALX Oncology (NASDAQ:ALXO), Aptose Biosciences (NASDAQ:APTO), Blueprint Medicines (NASDAQ:BPMC), Clovis (NASDAQ:CLVS), Deciphera (NASDAQ:DCPH), Fate Therapeutics (NASDAQ:FATE), IGM Biosciences (NASDAQ:IGMS), ImmunoGen (NASDAQ:IMGN), Incyte (NASDAQ:INCY), Iovance Biotherapeutics (NASDAQ:IOVA), iTeos Therapeutics (NASDAQ:ITOS), Kura Oncology (NASDAQ:KURA), Mirati Therapeutics (NASDAQ:MRTX), Seattle Genetics (NASDAQ:SGEN), Sutro Biopharma (NASDAQ:STRO), Syros Pharmaceuticals (NASDAQ:SYRS), TCR2 Therapeutics (NASDAQ:TCRR) and Xencor (NASDAQ:XNCR).
  • J
    John D
    Good news for the IMGN longs:

    https://www.youtube.com/watch?v=HLrqsT2ZHv4
    Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer
    www.youtube.com
    Bullish
  • a
    aaa
    Even if this stock moved up significantly...I would still believe that the CEO should be replaced. This company's stock has disappointed shareholders for years...and that lays directly on the CEO. Look at Elon Musk...he sells his company to investors, through tweets, and other venues. His stock is strong because he is a super salesman....
  • A
    AnthonyH
  • S
    Sergio
    It's going to be funny to see the herd buying this week only because It has a similar name to IMMU. Opportunity to sell high and buy back cheaper later. 10 years ago I wouldn't even consider such a lame tactic, but, this is how the market works now.
    Bullish
  • W
    Wayne
    This will be the next IMMU, good entry point at current price, load it up. I had IMMU for 8 years, IMGN will not take that long to reward patience investor.
    Bullish
  • B
    Booda
    IMMU got buyout offer of 20B, and they have ADC products, but this one is just going backward every day!!
  • m
    marcos
    Imgn mgmt price we don’t care about the stock price we get our shares for free and look at our track record we never and I mean never buy the stock in the open market no matter how low it goes.
  • A
    AnthonyH
    ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.
    ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.
    seekingalpha.com
  • Y
    Yahoo Finance Insights
    Immunogen is up 8.91% to 4.22
  • m
    marcos
    I’m dying to see how much the short interest has grown this quarter.i bet most of the daily volume is people shorting this stock
  • F
    Frank
    Time to light a candle under this one....
  • T
    Tony
    Bullish
  • l
    lonely
    What is the reason for continuing Down ??
  • T
    Tony
    It is disgusting how people like Jeff get so eluted about shorting a life-saving drug developing biotech. I really hope you or one of your loved doesn't end up getting cancer. So many companies to short out there - go for the one that is trying to save lives on the way. Anyway IMGN is a very predictable stock, and based on its current pipeline (the best it has ever managed to bring along since the 80s), and the extremely strong institutional support/hedge funds backing it, one morning you'll wake up and get fried. Shorties are too predictable and also good when the stock starts running as they have to get covered quickly and we go up! Go IMGN!
    Bullish
  • J
    John D
    someone just bought 1.5m after market according to the Village boys
  • J
    John D
    I believe the market makers are trying to keep the price low as they accumulate so that when everything comes together, BIG PAYDAY-For them and those who are long! (Please no replies from Marcos or Jeff)
    Bullish